On October 7, 2021 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported the presentation of preclinical data on the company’s new immuno-oncology program targeting CD27 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Conference on Tumor Immunology and Immunotherapy (Press release, Kineta, OCT 7, 2021, View Source;utm_medium=rss&utm_campaign=kineta-presents-preclinical-data-on-its-new-cd27-program-at-the-aacr-conference-on-tumor-immunology-and-immunotherapy [SID1234590928]). Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, presented a poster detailing new preclinical data on the company’s lead anti-CD27 agonist antibodies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CD27 is a member of the TNF receptor superfamily and plays a critical role in T-cell activation by providing a co-stimulatory signal together with its ligand CD70. CD27 is highly expressed on naïve T cells and also provides a co-stimulatory signal for NK cell activation. A major challenge in cancer immunotherapy is T cell "exhaustion". Anti-cancer T cells, through repeated stimulation, begin to lose their cancer-fighting effector functions. Once a T cell is exhausted, further stimulation becomes ineffective. CD27 agonist immunotherapy may reprogram the immune system to generate new and more diverse populations of anticancer "memory" T cells from naïve T cells to elicit a strong anti-tumor response.

"This is a significant milestone for Kineta as we expand our pipeline with another exciting immuno-oncology antibody program," said Shawn Iadonato, PhD, Chief Executive Officer of Kineta. "Our immuno-oncology strategy is to develop differentiated immunotherapies to address key mechanisms of cancer resistance including immunosuppression, exhausted T cells, and lack of tumor antigens. CD27 is a promising immunotherapy target to address exhausted T cells and restore anti-tumor T cell function".

Key results from the AACR (Free AACR Whitepaper) poster presentation include the following:

147 fully human monoclonal anti-CD27 antibodies with unique sequences were generated
Kineta’s anti-CD27 antibodies are highly specific and cross-react with cyno-CD27
Anti-CD27 agonist assay showed particularly strong induction for eight of the anti-CD27 antibodies
Human peripheral blood T cell activation assay showed increased proliferation and cytokine secretion
"We are encouraged with the results of our anti-CD27 antibodies as they performed exceedingly well across multiple preclinical experiments", said Thierry Guillaudeux, PhD, SVP Immuno-oncology at Kineta. "We are currently in lead selection and will nominate a clinical candidate to advance into IND-enabling studies in 2022."

Presentation Details:

Title: A promising cancer immunotherapy target: Novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27
Date Presented: October 5-6, 2021
Presenter: Thierry Guillaudeux, PhD
Poster: Click on the link below to view the poster:
Kineta CD27 Poster Presentation at AACR (Free AACR Whitepaper) Conference on Tumor Immunology and Immunotherapy